**Chondrosarcoma - Pipeline Review, H1 2015**

**Description:** Chondrosarcoma - Pipeline Review, H1 2015

**Summary**

This, 'Chondrosarcoma - Pipeline Review, H1 2015', provides an overview of the Chondrosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chondrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chondrosarcoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

**Note**: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

**Scope**

- The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chondrosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chondrosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chondrosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

**Reasons to buy**

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chondrosarcoma Overview
Therapeutics Development
Pipeline Products for Chondrosarcoma - Overview
Pipeline Products for Chondrosarcoma - Comparative Analysis
Chondrosarcoma - Therapeutics under Development by Companies
Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes
Chondrosarcoma - Pipeline Products Glance
Clinical Stage Products
Chondrosarcoma - Products under Development by Companies
Chondrosarcoma - Products under Investigation by Universities/Institutes
Chondrosarcoma - Companies Involved in Therapeutics Development
Agios Pharmaceuticals, Inc.
Celgene Corporation
CytRx Corporation
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
Chondrosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AG-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-90007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chondrosarcoma - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3330529/
Office Code: SCD22DNT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________________ Last Name: ___________________________________
Email Address: * ___________________________________
Job Title: _______________________________________
Organisation: ___________________________________
Address: _______________________________________
City: _________________________________________
Postal / Zip Code: _______________________________
Country: _______________________________________
Phone Number: ___________________________________
Fax Number: ___________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World